cardiology careers collections past issues search home
     

J Am Coll Cardiol, 1989; 13:904-910
© 1989 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Niazi, I
Right arrow Articles by Akhtar, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niazi, I
Right arrow Articles by Akhtar, M

Treatment of atrioventricular node reentrant tachycardia with encainide: reversal of drug effect with isoproterenol

I Niazi, G Naccarelli, A Dougherty, R Rinkenberger, P Tchou, and M Akhtar

Natalie and Norman Soref and Family Electrophysiology Laboratory, University of Wisconsin-Milwaukee Clinical Campus, Sinai Samaritan Medical Center.

To determine the efficacy of encainide in the treatment of atrioventricular (AV) node reentrant tachycardia, Holter electrocardiographic (ECG) monitoring, exercise treadmill testing and programmed electrical stimulation were performed in 16 patients while they were taking no medication and after steady state levels were reached during treatment with encainide (75 to 200 mg/day; mean 117 +/- 47). In addition, to study the possible reversal of drug effects by sympathetic stimulation, AV node conduction and tachycardia induction were reassessed during isoproterenol infusion (1 to 3 micrograms/min), a dose calculated to increase the rest heart rate by 25 +/- 10%. Sustained AV node reentrant tachycardia could be initiated in all 16 patients in the control state, in 2 patients after encainide and in 10 patients during isoproterenol infusion. The shortest mean atrial paced cycle length sustaining 1:1 AV conduction was 358 +/- 57 ms during the control study, which increased to 409 +/- 59 ms with encainide (p less than 0.01 versus control) and decreased to 313 +/- 31 ms during isoproterenol infusion (p less than 0.01 versus control and encainide). The shortest mean ventricular paced cycle length with 1:1 ventriculoatrial conduction was 337 +/- 56 ms in the control study, 551 + 124 ms with encainide infusion (p less than 0.01 versus control) and 354 +/- 72 ms during isoproterenol infusion in the encainide-loaded state (p less than 0.01 versus both control and encainide). During a mean follow-up period of 19 +/- 10 months, significant clinical recurrences occurred in 4 of the 10 patients in whom tachycardia could still be initiated with encainide (with or without isoproterenol).(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
CirculationHome page
K. T. Cragun, S. B. Johnson, and D. L. Packer
ß-Adrenergic Augmentation of Flecainide-Induced Conduction Slowing in Canine Purkinje Fibers
Circulation, October 21, 1997; 96(8): 2701 - 2708.
[Abstract] [Full Text]



 
  cardiology careers collections past issues search home